Open an account

Tonix Pharmaceuticals Holding

TNXP · NASDAQ

$5.78+$0.05 (+0.87%)TodayMarket closed ·
Prev close $5.73

About TNXP

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 142 full-time employees. The company went IPO on 2010-03-29. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Employees
142
Headquarters
Chatham, New Jersey
Listed
Mar 29, 2010
Sector
Health Care
Industry
Biotechnology
Website
tonixpharma.com

TNXP key statistics

Market cap
99.13M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
980.55K
Volume
621.37K
Open price
$5.73
High today
$6.04
Low today
$5.55
52 Week high
$20.58
52 Week low
$5.61

Tonix Pharmaceuticals Holding (TNXP) at a glance

As of Oct 20, 2026, Tonix Pharmaceuticals Holding (TNXP) shares are priced at $5.78, giving the company a market cap of 99.13M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.55 and $6.04. The current price is 4.2% above the day's low and 4.3% below its high.

Volume so far is 621.37K shares, below the average of 980.55K shares a day.

Over the past year Tonix Pharmaceuticals Holding has ranged from $5.61 to $20.58, and now sits 1% of the way up that range.

Tonix Pharmaceuticals Holding met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$2.44 per share against an estimate of -$2.75.

The average analyst price target is $43.25, 648.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $43.25
Low
$22.22
Now
$5.78
High
$68.25

TNXP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 43.4% on average.

  1. Q3 FY24: reported -$23.00 per share against an estimate of -$299.20
  2. Q4 FY24: reported -$9.77 per share against an estimate of -$394.86
  3. Q1 FY25: reported -$2.84 per share against an estimate of -$3.29
  4. Q2 FY25: reported -$3.86 per share against an estimate of -$3.28
  5. Q3 FY25: reported -$3.59 per share against an estimate of -$3.66
  6. Q4 FY25: reported -$3.98 per share against an estimate of -$3.25
  7. Q1 FY26: reported -$2.93 per share against an estimate of -$2.48
  8. Q2 FY26: reported -$2.44 per share against an estimate of -$2.75

TNXP news

  • Press releaseGlobe Newswire

    Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

  • Press releaseGlobe Newswire

    Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

  • Press releaseGlobe Newswire

    Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

  • Press releaseGlobe Newswire

    Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

  • Dylan Berman

    Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA

  • Press releaseGlobe Newswire

    Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

  • Dylan Berman

    Why Tonix Pharmaceuticals Shares Are Rallying Wednesday

Similar companies

Companies in the same industry as Tonix Pharmaceuticals Holding

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.